Skip Navigation


Brain Advance Access originally published online on October 8, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
127/1/34    most recent
awh001v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Buss, A.
Right arrow Articles by Schmitt, A. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buss, A.
Right arrow Articles by Schmitt, A. B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 127, No. 1, 34-44, 2004
© 2004 Guarantors of Brain
doi: 10.1093/brain/awh001

Gradual loss of myelin and formation of an astrocytic scar during Wallerian degeneration in the human spinal cord

A. Buss1, G. A. Brook1, B. Kakulas2, D. Martin3,4,5, R. Franzen5, J. Schoenen4,5, J. Noth1 and A. B. Schmitt1

1 Department of Neurology, Aachen University Medical School, Pauwelsstrasse 30, Germany, 2 Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Australia, and 3 Department of Neurosurgery, Sart Tilman Hospital, 4 Department of Neurology and Neuropathology and 5 Center for Cellular and Molecular Neuroscience, University of Liège, Liège, Belgium

Correspondence to: Armin Buss, Department of Neurology, Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, Germany E-mail: arminbuss{at}hotmail.com

Axons undergo Wallerian degeneration distal to a point of injury. Experimental investigations have documented many of the cellular and molecular events that underlie this behaviour. Since relatively little is known about such events in human CNS pathologies and current experimental intervention strategies indicate the possibility of significant axon regeneration along the original degenerated fibre tract, we performed an immunohistochemical investigation of the dynamics of Wallerian degeneration in post mortem spinal cords of patients who died 2 days to 30 years after either cerebral infarction or traumatic spinal cord injury. Neurofilament (NF) staining demonstrated a spatio-temporal pattern of axonal loss within degenerating descending nerve fibre tracts that could be detected close to the lesion as early as 12 days after injury and progressed to an almost complete loss of NF immunoreactivity at survival times of 1 year and longer. Immunohistochemistry for glial fibrillary acidic protein revealed a late astrocytic reaction starting at 4 months after injury in the degenerating tracts, leading to the long-term deposition of a dense astrocytic scar. These events were accompanied by the gradual reduction of myelin basic protein in affected nerve fibre tracts, leading to almost complete loss by 3 years after injury. Since the extracellular matrix molecule chondroitin sulphate proteoglycan (CSPG) is known to be strongly inhibitory for axonal regeneration and to be a major component of gliotic scar tissues, we investigated the possible deposition of CSPG within the degenerating nerve fibre tracts. Apart from a local up-regulation close to the lesion site, our results show no enhanced CSPG expression within degenerated tracts at any survival time. This suggests that despite the apparent lack of CSPG in Wallerian degeneration, the slow reduction of CNS myelin and the long-term deposition of a dense astrocytic scar may present an environment that is non-supportive for axon regrowth.

Key Words: astrocyte; CSPG; GFAP; myelin; Wallerian degeneration

Abbreviations: CSPG = chondroitin sulphate proteoglycan; CST = corticospinal tract; GFAP = glial fibrillary acidic protein; MBP = myelin basic protein; NF = neurofilament

Received March 18, 2003. Revised July 8, 2003. Accepted July 17, 2003.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cereb CortexHome page
P.J. Wrigley, S.M. Gustin, P.M. Macey, P.G. Nash, S.C. Gandevia, V.G. Macefield, P.J. Siddall, and L.A. Henderson
Anatomical Changes in Human Motor Cortex and Motor Pathways following Complete Thoracic Spinal Cord Injury
Cereb Cortex, January 1, 2009; 19(1): 224 - 232.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
A. Buss, K. Pech, B. A. Kakulas, D. Martin, J. Schoenen, J. Noth, and G. A. Brook
Growth-modulating molecules are associated with invading Schwann cells and not astrocytes in human traumatic spinal cord injury
Brain, April 1, 2007; 130(4): 940 - 953.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
J H Simon
Brain atrophy in multiple sclerosis: what we know and would like to know
Multiple Sclerosis, November 1, 2006; 12(6): 679 - 687.
[Abstract] [PDF]


Home page
BrainHome page
A. Buss, K. Pech, D. Merkler, B. A. Kakulas, D. Martin, J. Schoenen, J. Noth, M. E. Schwab, and G. A. Brook
Sequential loss of myelin proteins during Wallerian degeneration in the human spinal cord
Brain, February 1, 2005; 128(2): 356 - 364.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. M. Graham, N. Papadakis, J. Evans, E. Widjaja, C. A.J. Romanowski, M. N.J. Paley, L. I. Wallis, I. D. Wilkinson, P. J. Shaw, and P. D. Griffiths
Diffusion tensor imaging for the assessment of upper motor neuron integrity in ALS
Neurology, December 14, 2004; 63(11): 2111 - 2119.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.